EMEA-002736-PIP02-23
Submitted by Anonymous (not verified) on 6 June 2025 - 14:29
EMEA-002736-PIP02-23
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0102/2024
Submitted by Anonymous (not verified) on 6 June 2025 - 14:27
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0102/2024
EMEA-003569-PIP01-23
Submitted by Anonymous (not verified) on 6 June 2025 - 14:20
EMEA-003569-PIP01-23
EMEA-003405-PIP01-23
Submitted by Anonymous (not verified) on 6 June 2025 - 11:09
EMEA-003405-PIP01-23
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025
Submitted by Anonymous (not verified) on 6 June 2025 - 11:00
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025
PSUSA/00001842/202410
Submitted by Anonymous (not verified) on 6 June 2025 - 10:45
PSUSA/00001842/202410
EMEA-003313-PIP03-23
Submitted by Anonymous (not verified) on 6 June 2025 - 9:36
EMEA-003313-PIP03-23
EMEA-003540-PIP01-23
Submitted by Anonymous (not verified) on 6 June 2025 - 8:54
EMEA-003540-PIP01-23
EMEA-003537-PIP01-23
Submitted by Anonymous (not verified) on 6 June 2025 - 8:47
EMEA-003537-PIP01-23
EMEA-003528-PIP01-23
Submitted by Anonymous (not verified) on 6 June 2025 - 8:41
EMEA-003528-PIP01-23